• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Recent Advances in the Study of 3-(Pyrrolidin-1-yl)methylpyridine (CAS: 370-09-2)

3-(Pyrrolidin-1-yl)methylpyridine (CAS: 370-09-2) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its pyrrolidine and pyridine moieties, has been the subject of recent investigations due to its potential applications in drug discovery and development. The unique structural features of 3-(pyrrolidin-1-yl)methylpyridine make it a promising candidate for modulating biological targets, particularly in the central nervous system (CNS) and as a building block for more complex pharmacophores.

Recent studies have focused on the synthesis, characterization, and biological evaluation of 3-(pyrrolidin-1-yl)methylpyridine and its derivatives. A 2023 publication in the Journal of Medicinal Chemistry highlighted its role as a precursor in the synthesis of novel nicotinic acetylcholine receptor (nAChR) modulators. The study demonstrated that derivatives of this compound exhibit selective binding to α4β2 nAChR subtypes, which are implicated in cognitive functions and neuropsychiatric disorders. These findings suggest potential therapeutic applications for conditions such as Alzheimer's disease and schizophrenia.

In addition to its CNS applications, 3-(pyrrolidin-1-yl)methylpyridine has been explored in the context of antimicrobial agents. A 2022 study published in Bioorganic & Medicinal Chemistry Letters reported the synthesis of a series of derivatives with significant activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compound's ability to disrupt bacterial cell membrane integrity, a mechanism distinct from traditional antibiotics, thereby reducing the likelihood of resistance development.

Another area of interest is the compound's potential in cancer research. Preliminary in vitro studies conducted in 2023 indicated that certain derivatives of 3-(pyrrolidin-1-yl)methylpyridine exhibit cytotoxic effects against various cancer cell lines, particularly those associated with breast and lung cancers. These effects are believed to be mediated through the inhibition of key signaling pathways involved in cell proliferation and survival. While these findings are promising, further in vivo studies are required to validate the compound's efficacy and safety profile.

The pharmacokinetic properties of 3-(pyrrolidin-1-yl)methylpyridine have also been a focus of recent research. A 2023 pharmacokinetic study published in Drug Metabolism and Disposition revealed that the compound exhibits favorable absorption and distribution characteristics, with moderate plasma protein binding and good blood-brain barrier penetration. These properties make it an attractive candidate for further development, particularly for CNS-targeted therapies.

Despite these advancements, challenges remain in the development of 3-(pyrrolidin-1-yl)methylpyridine-based therapeutics. Issues such as metabolic stability, potential off-target effects, and the need for more selective derivatives are areas of active investigation. Recent computational studies utilizing molecular docking and dynamics simulations have provided insights into structure-activity relationships, aiding in the design of more potent and selective analogs.

In conclusion, 3-(pyrrolidin-1-yl)methylpyridine (CAS: 370-09-2) represents a versatile scaffold with diverse pharmacological potential. Recent studies have expanded our understanding of its applications in CNS disorders, antimicrobial therapy, and oncology. Continued research into its derivatives and mechanisms of action is likely to yield novel therapeutic agents in the coming years. The compound's unique chemical properties and promising biological activities make it a valuable focus for ongoing and future research in the chemical biology and pharmaceutical fields.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)